|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?显示文摘Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma(HCC) since 2007 and numerous studieshave investigated the role of markers involved in the angiogenesis process at both the expression and genetic level and clinical aspect. What results have ten years of research produced? Several clinical and biological markers are associated with prognosis. The most interesting clinical parameters are adverse events, Barcelona Clinic Liver Cancer stage, and macroscopic vascular invasion, while several single nucleotide polymorphisms and plasma angiopoietin-2 levels represent the most promising biological biomarkers. A recent pooled analysis of two phase III randomized trials showed that the neutrophil-to-lymphocyte ratio, etiology and extra-hepatic spread are predictive factors of response to sorafenib, but did not identify any predictive biological markers. After 10 years of research into sorafenib there are still no validated prognostic or predictive factors of response to the drug in HCC. The aim of the present review was to summarize 10 years of research into sorafenib, looking in particular at the potential of associated clinical and biological markers to predict its efficacy in patients with advanced HCC. | Giorgia Marisi Alessandro Cucchetti Paola Ulivi Matteo Canale Giuseppe Cabibbo Leonardo Solaini Francesco G Foschi Serena De Matteis Giorgio Ercolani Martina Valgiusti Giovanni L Frassineti Mario Scartozzi Andrea Casadei Gardini | 2018 | World Journal of Gastroenterology2018，24，36： | 14 |
| 2 | Current concepts in ameloblastoma-targeted therapies in B-raf proto-oncogene serine/threonine kinase V600E mutation: Systematic review显示文摘BACKGROUND Ameloblastomas are common benign epithelial odontogenic neoplasms that present an aggressive and unpredictable behavior that may modify treatment strategies.Different signaling pathways that participate in the progression of these tumors have been identified.B-raf proto-oncogene serine/threonine kinase(BRAF)is a protein involved in the behavior of ameloblastomas,and it is related to many cell mechanisms.BRAF gene mutations have been identified in ameloblastomas,of which the BRAF V600E(valine substituted by glutamic acid at amino acid 600)mutation has been the most common and can be present concomitantly with other mutations that may be involved in its behavior.Targeted therapies have been used as an alternative in the case of resistance or contraindications to conventional treatments.AIM To document the presence of BRAF V600E and additional mutations,their behavior,and targeted therapies in these tumors.METHODS An electronic literature search was conducted according to PRISMA guidelines in PubMed/MEDLINE,Cochrane,EMBASE,and SpringerLink using the terms“ameloblastomas”,“BRAF V600E”,“additional mutations”,and“targeted therapies”.Ameloblastomas were classified according to WHO guidelines.Inclusion criteria were articles in English,published not more than 10 years ago,and studies with laboratory works related to BRAF V600E.Articles were evaluated by two independent reviewers and retrieved for full-text evaluation.The EBLIP Critical Appraisal Checklist was used to evaluate the quality of the eligible studies.Descriptive statistical analysis was performed.RESULTS Two independent reviewers,with a substantial concordance indicated by a kappa coefficient of k=0.76,evaluated a total of 19 articles that were included in this study.The analysis registered 521 conventional ameloblastomas(AM),81 unicystic ameloblastomas(UA),13 ameloblastic carcinomas(AC),three metastatic ameloblastomas(MA),and six peripheral ameloblastomas(PA),of which the histopathological type,anatomic location,laboratory tests,expression of BRAF mutation,and additional mutations were registered.The BRAF V600E mutation was found in 297 AM(57%),63 UA(77.7%),3 AC(23%),1 MA(50%),and 5 PA(83.3%).Follicular type predominated with a total of 116 cases(40%),followed by plexiform type with 63 cases(22.1%).Furthermore,both types presented additional mutations,in which alterations in JAK3 P132T,SMARCB1,PIK3CA,CTNNB1,SMO,and BRAF G606E genes were found.Four case reports were found with targeted therapy to BRAF V600E.CONCLUSION The identification of BRAF V600E and additional mutations as an aid in targeted therapies has been a breakthrough in alternative treatments of ameloblastomas where surgical treatments are contraindicated. | Rogelio González-González Sandra López-Verdín Jesús Lavalle-Carrasco Nelly Molina-Frechero Mario Isiordia-Espinoza Ramón G Carreón-Burciaga Ronell Bologna-Molina | 2020 | World Journal of Clinical Oncology2020，11，1： | 6 |
| 3 | Eosinophilic esophagitis: Current concepts in diagnosis and treatment显示文摘Eosinophilic esophagitis is an immune-allergic pathology of multifactorial etiology(genetic and environmental)that affects both pediatric and adult patients.Its symptoms,which include heartburn,regurgitation,and esophageal stenosis(with dysphagia being more frequent in eosinophilic esophagitis in young adults and children),are similar to those of gastroesophageal reflux disease,causing delays in diagnosis and treatment.Although endoscopic findings such as furrows,esophageal mucosa trachealization,and whitish exudates may suggest its presence,this diagnosis should be confirmed histologically based on the presence of more than 15 eosinophils per high-power field and the exclusion of other causes of eosinophilia(parasitic infections,hypereosinophilic syndrome,inflammatory bowel disease,among others)for which treatment could be initiated.Currently,the 3“D”s(“Drugs,Diet,and Dilation”)are considered the fundamental components of treatment.The first 2 components,which involve the use of proton pump inhibitors,corticosteroids,immunosuppressants and empirical diets or guided food elimination based on allergy tests,are more useful in the initial phases,whereas endoscopic dilation is reserved for esophageal strictures.Herein,the most important aspects of eosinophilic esophagitis pathophysiology will be reviewed,in addition to evidence for the various treatments. | Andrés Gómez-Aldana Mario Jaramillo-Santos Andrés Delgado Carlos Jaramillo Adán Lúquez-Mindiola | 2019 | World Journal of Gastroenterology2019，25，32： | 2 |
| 4 | Treatment of full- thickness chondral defects of the knee with autologous chondro- cyte implantation: a functional evaluation with long-term fol- low-up 显示文摘 | Alexandros E B Marios G L Agnantis K | 2012 | The American journal of sports medicine2012，40，3： | 1 |
| 5 | Clinical usefulness of serum pepsinogens I and II,gastrin-17 and anti-Helicobacterpylori antibodies in the management of dyspeptic patients in primary care显示文摘 | GERMAN(A) B DI MARIO F CAVALLARO L G | | 0，，： | 1 |
| 6 | Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism显示文摘 | Santos S H Fernandes L R Mario E G | 2008 | Diabetes2008，57，： | 1 |
| 7 | A low-cost 3D reconstruction system using a single-shot projection of a pattern matrix显示文摘 | MARIO L R ANTONIO T G | | 0，，113： | 1 |
| 8 | Non-invasive tests in gas-tric diseases 显示文摘 | Di Mario F Cavallaro L G | 2008 | Dig Liver Dis2008，40，7： | 1 |
| 9 | Perinatal Exposure to Low Doses of Dioxin Can Permanently Impair Human Semen Quality显示文摘 | Mocarelli Paolo Gerthoux Pier Mario Needham Larry L Patterson Donald G Limonta Giuseppe Falbo Rosanna Signorini Stefano Bertona Maria Crespi Carla Sarto Cecilia Scott Paul K Turner Wayman E Brambilla Paolo | 2011 | Environmental Health Perspectives2011，，5： | 1 |
| 10 | Role of V-ATPases in solid tumors : importance of the subunit C : review 显示文摘 | Mario P S Abel G G Maria D R L | 2009 | Int J Oncol2009，34，6： | 1 |
| 11 | Herpes SimplexVirus Keratitis : Epidemiological Observations 显示文摘 | Virgilio G Alejandro T Mario L R | 2013 | Survey of Ophthalmology2013，58，3： | 1 |
| 12 | Effects of polymer addition on the rheology of O/W microemulsions显示文摘 | ROMANNO L MARIO G NICOLETTA C | 2001 | Rheol Acta2001，，40： | 1 |
| 13 | Surgical anatomy and landmarks for the basal vein of Rosenthal 显示文摘 | R Shane Tubbs Marios L Robert G | 2007 | J Neurosurg2007，，106： | 1 |
| 14 | Rescue'thera-pies for the management of Helicobacter pylori infection显示文摘 | DI MARIO F CAVALLARO L G SCARPIGNATO C | 2006 | Dig Dis2006，24，12： | 1 |
| 15 | Mas deficiency inFVB/N mice produces marked changes in lipid and glycemicmetabolism 显示文摘 | Santos S H Fernandes L R Mario E G ei al | 2008 | Diabetes2008，57，2： | 1 |
| 16 | Rac-topamine effect on lipid metabolism and GLUT4amount of finishing pigs显示文摘 | Araujo T S Jardim Porto L C Mario E G | 2014 | Turkish Journal of Vet-erinary Animal Sciences2014，38，1： | 1 |
| 17 | A gene cluster involved in metal homeostasis in the cyanobacterium synechocystis sp strain PCC 6803显示文摘 | Mario G Luis L | 2000 | Journal of Bacteriology2000，182，6： | 1 |
| 18 | ' Rescue ' Therapiesfor t he Management of Helicobacter Pylori Infection 显示文摘 | Di Mario F Cavallaro L G Scarpignato C | 2006 | DigDis2006，24，12： | 1 |
| 19 | Use of mesalazine in diverticular disease显示文摘 | Di Mario F Comparato G Fanigliulo L | 2006 | J Clin Gastroenterol2006，40，73： | 1 |
| 20 | TCP with delayed ack for wireless networks显示文摘 | Jiwei C Mario G Yengzhong L | 2008 | Adhoc Networks2008，6，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员